Crucell N.V.

Mr. Björn Sjöstrand is Chief Business Officer and a member of Crucell’s Management Committee. He was Chief Executive Officer at SBL Vaccines before it was acquired by Crucell in November 2006. He headed the Crucell-SBL integration committee and directed the travel franchise and the Nordic sales force for the Crucell Group. Prior to that, he worked as Vice President Operations & IT at Active Biotech and was a member of the Senior Management Team. He completed a Bachelor of Science degree in Economics and Business Administration at the University of Örebro, Sweden. He also studied Financial Investment theory and Commercial law at the same university.

Dr. Cees de Jong joined Crucell as Chief Operating Officer in September 2007, after working at Quest International in Naarden, the Netherlands, as a member of the Board responsible for the Flavours Division. Prior to Quest, he worked as Managing Director of DSM Anti-infectives. In 1989 he started his career at Gist Brocades, holding a variety of roles in Business Development, Strategy and General Management before the company’s acquisition by DSM in 1998. He holds a medical degree and earned an MBA at the Erasmus University, Rotterdam, the Netherlands.

Mr. Kruimer has been Chief Financial Officer since joining Crucell in 1998 and is a member of Crucell’s Management Board and Management Committee. Prior to Crucell, he held interim executive positions at Pepsico and Royal Boskalis Westminster. From 1993 to 1995, he was Managing Director Continental Europe at TIP Europe, a unit of GE Capital. Prior he held senior executive positions at Kwik-Fit Europe and Continental Can Europe. He was a consultant with McKinsey & Co and started his career at PriceWaterhouse & Co in New York. He holds an MBA from the Harvard Graduate School of Business Administration and an undergraduate degree from the University of Massachusetts. He is a CPA in New York State.

Professor and Chairman of the Department of Immunology at the Faculty of Medicine, University of Utrecht Medical Center since 1991. He is one of the leading experts in the field of the genetic analysis of signalling pathways, in particular the Wnt / -Catenin / Tcf pathway and one of the scientific founders of Semaia Pharmaceuticals. Prof. Clevers is also a co-founder and Scientific Advisory Board Member of Crucell of Leiden, the Netherlands, and member of the Scientific Advisory Board of Jari Therapeutics, Utrecht, the Netherlands.

Mr. Beukema is Crucell’s General Counsel and Corporate Secretary since the Company’s incorporation. He held the same position at IntroGene after joining the company in 1999. From 1994 to 1999, he was Senior Legal Counsel for GE Capital/TIP Europe. From 1991 to 1994, he was Legal Counsel for TNT Express Worldwide N.V. He has a Masters in Law from the University of Amsterdam, the Netherlands.

Arnold Hoevenaars has been attending our Supervisory Board meetings as an observer since July 2004, and was officially appointed to the board at our AGM on June 2, 2005. Mr Hoevenaars is a chartered accountant in the Netherlands, and his previous positions include, among other, Chairman of the Management Board of the Achmea Group, Chairman of the Board of Directors and Chairman/CEO of the Executive Board of Eureko B.V. and member of the Management Board and Chief Financial Officer of Royal Boskalis Westminster N.V.

Mr. Satow was appointed to Noven's Board of Directors in August 2007 upon the closing of Noven's acquisition of JDS Pharmaceuticals, LLC. Mr. Satow was JDS's co-founder and served as its Chief Executive Officer from inception in August 2004 through completion of the acquisition. After 15 years with Pfizer and three years as Vice President and General Manager of the Carter Wallace pharmaceutical business, Mr. Satow served as Executive Vice President of Forest Laboratories and President of its Forest Pharmaceuticals subsidiary. He established the marketing and sales departments at Forest, which he led for 14 years through the launch of Forest's highly-successful antidepressant Celexa .

Dr. Ronald Brus is Crucell?s President and Chief Executive Officer. He has been a member of Crucell?s Management Committee since the Company?s incorporation and was formerly Chief Operating Officer (March 2003 to January 2004) and Chief Business Officer (October 2000 to February 2003). Prior to that, he was Executive Vice President Business Development after joining the Company in 1997. From 1994 to 1996 he was product planning physician at Forest Laboratories in New York and from 1990 to 1994 he was Medical Director for Zambon B.V. He holds a medical degree from the University of Groningen, the Netherlands.

Seán Lance has served as a member of our Supervisory Board since January, 2004. Mr Lance is Chairman of Chiron Corporation. He joined Chiron as President and CEO in 1998. From 1985 to 1998 he was with Glaxo Holdings where his last position was group Chief Operating Officer and CEO designate. He is a past President of the International Federation of Pharmaceutical Manufacturers Association. Mr Lance is a chartered company secretary and administrator and he also holds a post-graduate qualification in Advanced Financial Management.

Steve Davis has been appointed during the 2008 AGM as a member of our Supervisory Board. Mr. Davis was CEO of Corbis until 2007 and now acts as a senior advisor to the company. He has held positions within the United Nations High Commissioner for Refugees and several refugee resettlement programs. Currently he is a member of the Board of Trustees for PATH, a non-profit organization focused on improving public health in the developing world. He is a member of the Board of Trustees for the Fred Hutchinson Cancer Research Center. He holds a board position in Intrepid Learning Solutions, Seattle Foundation, and PlanetOut Inc.

Former president and chief executive officer of Corbis, a global digital media company, managing rights and licensing images seen by millions of people daily in advertising, books, newspapers, magazines, television, and films. Mr. Davis had senior roles at Corbis from 1993 until 2007. Earlier, he practiced law with the firm of Preston Gates & Ellis in Seattle, specializing in intellectual property issues, and prior to that he held various positions in international refugee and human rights organizations. Davis received his AB from Princeton University, his MA in Chinese studies from the University of Washington, and his JD from Columbia University School of Law, where he received the Faculty Prize in international law. He has also attended certificate programs at Beijing University and Stanford Business School. Mr. Davis is active in numerous community and industry concerns. He currently serves on the boards of PATH, Fred Hutchinson Cancer Research Center, The Seattle Foundation, Global Partners, and PlanetOut, and is a member of the Council on Foreign Relations. He previously chaired the Technology Alliance, NPower, United Way of King County and the International Practice Section of the Washington State Bar and has served on the boards of the United Way International, Alliance for Education, Lambda Legal Defense & Education Fund, the Governor's Competiveness Council and other organizations.